MCID: NSP009
MIFTS: 23

Nasopharyngeal Carcinoma 2

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Gastrointestinal diseases

Aliases & Classifications for Nasopharyngeal Carcinoma 2

MalaCards integrated aliases for Nasopharyngeal Carcinoma 2:

Name: Nasopharyngeal Carcinoma 2 54
Nasopharyngeal Carcinoma, Susceptibility to, 2 13

Characteristics:

OMIM:

54
Inheritance:
questionably mendelian, but strong genetic factor involved


Classifications:



External Ids:

OMIM 54 161550
SNOMED-CT via HPO 65 108369006 363346000

Summaries for Nasopharyngeal Carcinoma 2

OMIM : 54
Nasopharyngeal carcinoma is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx (summary by Tse et al., 2009). For a general phenotypic description and a discussion of genetic heterogeneity of susceptibility to nasopharyngeal carcinoma, see NPCA1 (607107). (161550)

MalaCards based summary : Nasopharyngeal Carcinoma 2, is also known as nasopharyngeal carcinoma, susceptibility to, 2, and has symptoms including neoplasm An important gene associated with Nasopharyngeal Carcinoma 2 is NPCA2 (Nasopharyngeal Carcinoma, Susceptibility To, 2). The drugs Cisplatin and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver.

Related Diseases for Nasopharyngeal Carcinoma 2

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 3 Nasopharyngeal Carcinoma 2

Symptoms & Phenotypes for Nasopharyngeal Carcinoma 2

Symptoms via clinical synopsis from OMIM:

54

Misc:
hla linked gene confers greatly ineased risk
males more frequently affected than females
100-fold higher frequency in southern china than europe

Oncology:
nasopharyngeal cancer


Clinical features from OMIM:

161550

Human phenotypes related to Nasopharyngeal Carcinoma 2:

32
id Description HPO Frequency HPO Source Accession
1 neoplasm 32 HP:0002664

Drugs & Therapeutics for Nasopharyngeal Carcinoma 2

Drugs for Nasopharyngeal Carcinoma 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1 114977-28-5 148124 9877265
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Autonomic Agents Phase 4,Phase 3,Phase 2
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
12 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
13 Central Nervous System Stimulants Phase 4
14 Cholinergic Agents Phase 4
15 Nicotinic Agonists Phase 4
16 Antidepressive Agents Phase 4,Phase 3,Phase 2
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
19 Dopamine Agents Phase 4,Phase 2
20 Dopamine Uptake Inhibitors Phase 4,Phase 2
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
22
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
23
Nedaplatin Approved Phase 3,Phase 1,Phase 2 95734-82-0
24
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
25
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
26
Gemcitabine Approved Phase 2, Phase 3, Phase 1 95058-81-4 60750
27
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
28
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
29
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
30
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
31
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
32
Amifostine Approved, Investigational Phase 3,Phase 2 20537-88-6 2141
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Doxepin Approved Phase 3 1668-19-5 667477 667468
35
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
37
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
38
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 151165 6918365
39
Fosaprepitant Approved Phase 3,Phase 2 172673-20-0 219090
40
Palonosetron Approved, Investigational Phase 3,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
41
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
42 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
43
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
44
Substance P Investigational Phase 3,Phase 2 33507-63-0 44359816
45 Analgesics Phase 3,Phase 2,Phase 1
46 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
47 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 2,Phase 1
50 Cyclooxygenase 2 Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 317)

id Name Status NCT ID Phase Drugs
1 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Recruiting NCT02293356 Phase 4 Nimotuzumab Injection
5 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
6 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
7 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3 Hydroxyurea
8 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
9 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
10 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
11 Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma Unknown status NCT02089204 Phase 2, Phase 3
12 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
13 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
14 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
15 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
16 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
17 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
18 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
19 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
20 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
21 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
24 A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Recruiting NCT02512315 Phase 3 Docetaxel (DOC);Cisplatin (DDP)
25 Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02578641 Phase 3 combination IV gemcitabine and IV carboplatin (AUC2)
26 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
27 Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era Recruiting NCT02633202 Phase 3 Cisplatin
28 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02958111 Phase 3 Capecitabine
29 Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma Recruiting NCT02610010 Phase 3 Cisplatin
30 Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02434614 Phase 3 Docetaxel,Cisplatin,Fluorouracil;Cisplatin
31 Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients Recruiting NCT02973386 Phase 2, Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
32 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
33 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
34 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Recruiting NCT03006588 Phase 2, Phase 3
35 Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma Recruiting NCT02633176 Phase 3 Cetuximab;Cisplatin;Docetaxel;Capecitabine
36 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Recruiting NCT01817023 Phase 3 Cisplatin
37 Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients Recruiting NCT01744587 Phase 2, Phase 3
38 Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Recruiting NCT02135042 Phase 2, Phase 3 Cisplatin;Fluorouracil;Gemcitabine Hydrochloride;Paclitaxel
39 Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma Recruiting NCT02500940 Phase 3 Cisplatin;Fluorouracil;Leucovorin
40 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Recruiting NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
41 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
42 Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) Recruiting NCT02611960 Phase 3 Capecitabine;Gemcitabine;Docetaxel
43 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Recruiting NCT02395016 Phase 3 nimotuzumab;Gemcitabine
44 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
45 Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
46 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
47 Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Active, not recruiting NCT00379262 Phase 3 Capecitabine;Adjuvant chemotherapy using PF (5-Fluorouracil );Induction chemotherapy using PF (5-Fluorouracil)
48 Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC Active, not recruiting NCT00997906 Phase 2, Phase 3 carboplatin,;cisplatin;gemcitabine hydrochloride;paclitaxel
49 A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Active, not recruiting NCT00370890 Phase 3 Adjuvant chemotherapy (gemcitabine and cisplatin)
50 IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Not yet recruiting NCT03068936 Phase 3 Cisplatin

Search NIH Clinical Center for Nasopharyngeal Carcinoma 2

Genetic Tests for Nasopharyngeal Carcinoma 2

Anatomical Context for Nasopharyngeal Carcinoma 2

MalaCards organs/tissues related to Nasopharyngeal Carcinoma 2:

39
Lung, Brain, Liver, Bone, Breast, T Cells, Nk Cells

Publications for Nasopharyngeal Carcinoma 2

Variations for Nasopharyngeal Carcinoma 2

Cosmic variations for Nasopharyngeal Carcinoma 2:

9 (show top 50) (show all 434)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 9
2 COSM4995216 ZC3H13 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 9
3 COSM4995307 ZBTB17 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 9
4 COSM4995092 VPS33A upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 9
5 COSM4996600 VNN2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 9
6 COSM4995249 VANGL1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 9
7 COSM4996245 USP34 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 9
8 COSM4997193 USP19 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 9
9 COSM4995369 USH2A upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 9
10 COSM2978223 USH1G upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 9
11 COSM4995852 USE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 9
12 COSM4996719 TTBK1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 9
13 COSM4997149 TSR2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 9
14 COSM1524842 TSHZ3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 9
15 COSM4995873 TSHZ3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 9
16 COSM4995721 TRAF4 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 9
17 COSM2123037 TPR upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 9
18 COSM4996315 TP63 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 9
19 COSM10659 TP53 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.817C>T p.R273C 9
20 COSM10654 TP53 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 9
21 COSM10724 TP53 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 9
22 COSM43906 TP53 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 9
23 COSM1739496 TNKS upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.583G>A p.V195M 9
24 COSM4996454 TMPRSS11E upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.268G>T p.A90S 9
25 COSM4996730 TFAP2D upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.767C>A p.A256E 9
26 COSM4996391 TET2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.4250T>G p.V1417G 9
27 COSM4996386 TET2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.988G>C p.E330Q 9
28 COSM4996526 SYNPO upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1394C>A p.P465Q 9
29 COSM4996648 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.6506C>T p.T2169I 9
30 COSM4996618 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.21845G>C p.W7282S 9
31 COSM4996643 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.7996C>A p.Q2666K 9
32 COSM4996638 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.8339T>C p.L2780P 9
33 COSM4996653 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.5827G>A p.E1943K 9
34 COSM4996628 SYNE1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.14707G>T p.V4903L 9
35 COSM191830 SPTBN1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1916G>A p.R639H 9
36 COSM4995726 SPACA3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.376A>G p.N126D 9
37 COSM4994835 SORCS3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.3082G>A p.V1028I 9
38 COSM4995636 SMG1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1682A>G p.Y561C 9
39 COSM2128623 SMG1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.2699A>G p.N900S 9
40 COSM4996349 SMARCC1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.2927G>C p.G976A 9
41 COSM4997191 SLITRK3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.796C>T p.H266Y 9
42 COSM4996929 SLC7A2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.296C>A p.A99E 9
43 COSM4996458 SLC4A4 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.331C>G p.L111V 9
44 COSM4997189 SLC19A1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.758G>T p.R253L 9
45 COSM4994897 SIRT1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.568C>A p.Q190K 9
46 COSM4995400 SIPA1L2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.2574C>A p.H858Q 9
47 COSM2167722 SF3A3 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.1081G>A p.E361K 9
48 COSM4996346 SETD2 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.3808C>T p.R1270C 9
49 COSM4996834 SDK1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.6347T>G p.L2116R 9
50 COSM971349 SALL1 upper aerodigestive tract,nasopharynx,carcinoma,nasopharyngeal carcinoma c.2582C>T p.S861L 9

Expression for Nasopharyngeal Carcinoma 2

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma 2.

Pathways for Nasopharyngeal Carcinoma 2

GO Terms for Nasopharyngeal Carcinoma 2

Sources for Nasopharyngeal Carcinoma 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....